Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Upper gastrointestinal safety with nabumetone.

S H Roth1

  • 1Arthritis Center Ltd., Humana Hospital, Phoenix, AZ 85012.

The Journal of Rheumatology. Supplement
|November 1, 1992
PubMed
Summary

Nabumetone, a nonsteroidal anti-inflammatory drug (NSAID), shows a significantly lower incidence of gastrointestinal ulcers compared to other NSAIDs. Clinical studies confirm its safety profile with minimal ulcer development even in long-term use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whose pain is it anyhow?

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Finessing fibromyalgia.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2006
Same author

Anoxic depolarization of rat hippocampal slices is prevented by thiopental but not by propofol or isoflurane.

British journal of anaesthesia·2005
Same author

Small-dose pentobarbital enhances synaptic transmission in rat hippocampus.

Anesthesia and analgesia·2001
Same author

Arthritis therapy: a better time, a better day.

Rheumatology (Oxford, England)·2001
Same author

Effects of repeated hydrogen sulphide (H2S) exposure on learning and memory in the adult rat.

Neurotoxicology·2001

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Clinical Therapeutics

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
  • NSAID use is associated with significant gastrointestinal (GI) complications, including ulcers.
  • Nabumetone is a nonacidic NSAID with a reported favorable GI safety profile.

Purpose of the Study:

  • To evaluate the clinical incidence of gastrointestinal ulcers associated with nabumetone therapy.
  • To compare the ulcer incidence of nabumetone with general NSAID use and endoscopically determined rates.
  • To assess the long-term safety and tolerability of nabumetone regarding gastropathy.

Main Methods:

  • Review of clinical data from short-term (6-week to 6-month) and long-term (8-year) studies.
  • Analysis of endoscopically determined ulcer incidence in short-term (3-month) and long-term (5-year) studies.
  • Comparison of nabumetone ulcer rates against reported NSAID-related ulcer incidences from regulatory bodies and literature.

Main Results:

  • Clinically determined ulcer incidence with nabumetone was 0.1% (1/930) in short-term studies and 0.95% (16/1677) in a long-term study.
  • Endoscopically determined ulcer incidence was 5% (1/19) in a 5-year study, significantly lower than the approximately 20% seen with chronic NSAID use.
  • Nabumetone demonstrated a substantially reduced rate of ulcer development compared to general NSAID populations.

Conclusions:

  • Nabumetone exhibits a significantly lower incidence of gastrointestinal ulcer development compared to other NSAIDs.
  • The drug appears to cause minimal NSAID-induced gastropathy, supporting its favorable GI safety profile.
  • Clinical and endoscopic data suggest nabumetone is a safer alternative for patients at risk of NSAID-related GI complications.

Related Experiment Videos